Invention Grant
US07659302B2 Methods of using (+)-2-[1-(3-ethoxy-4 methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione
有权
使用(+) - 2- [1-(3-乙氧基-4-甲氧基苯基)-2-甲基磺酰基乙基] -4乙酰氨基异吲哚啉-1,3-二酮
- Patent Title: Methods of using (+)-2-[1-(3-ethoxy-4 methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione
- Patent Title (中): 使用(+) - 2- [1-(3-乙氧基-4-甲氧基苯基)-2-甲基磺酰基乙基] -4乙酰氨基异吲哚啉-1,3-二酮
-
Application No.: US12069282Application Date: 2008-02-08
-
Publication No.: US07659302B2Publication Date: 2010-02-09
- Inventor: George W. Muller , Peter H. Schafer , Hon-Wah Man , Chuansheng Ge
- Applicant: George W. Muller , Peter H. Schafer , Hon-Wah Man , Chuansheng Ge
- Applicant Address: US NJ Summit
- Assignee: Celgene Corporation
- Current Assignee: Celgene Corporation
- Current Assignee Address: US NJ Summit
- Agency: Jones Day
- Main IPC: A61K31/4035
- IPC: A61K31/4035 ; C07D209/44
![Methods of using (+)-2-[1-(3-ethoxy-4 methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione](/abs-image/US/2010/02/09/US07659302B2/abs.jpg.150x150.jpg)
Abstract:
Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (−) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-α or the inhibition of PDE4.
Public/Granted literature
Information query
IPC分类: